NDATOPICALLOTION
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRYHALI is a topical lotion formulation of halobetasol propionate, a potent Class I corticosteroid approved by the FDA in November 2018 for inflammatory skin conditions. The drug works by binding to glucocorticoid receptors to reduce inflammation, itching, and skin barrier dysfunction in dermatological indications.
$0.142MPart D
Peak5.2 years to LOEProduct is at peak commercial maturity with modest Part D utilization; team size likely stable with focus on market maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Career Relevance
BRYHALI careers are concentrated in commercial and medical affairs functions supporting a mature, peak-stage product with modest utilization (~330 Part D claims annually). Working on this product offers stability and deep expertise in dermatological marketing and sales, but limited growth trajectory absent clinical expansion or market share gains.
Brand Manager
Worked on BRYHALI at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.